Table 5. Categorical weight loss with weekly tirzepatide 10 mg or 15 mg in the SURMOUNT series of studies, according to the percentage of weight lost.
| Study/duration | Population | Loss > 5% | Loss > 10% | Loss > 15% | Loss > 20% |
|---|---|---|---|---|---|
| SURMOUNT-1 (72 weeks) (161) | Individuals with overweight or obesity and without T2DM | 90.9%* | 83.5%* | 70.6%* | 56.7%* |
| SURMOUNT-2 (72 weeks) (167) | Individuals with T2DM, with BMI > 27 kg/m2 and HbA1c between 7.0% and 10% | 79/83%** | 61/65%** | 40/48%** | 22/31%** |
| SURMOUNT-3 (72 weeks) (168) | Same as SURMOUNT-1; after 12 weeks, patients who achieved > 5% weight reduction with intensive lifestyle change were randomized to placebo or tirzepatide | 87.5% | 76.7% | 65.4% | 44.7% |
| SURMOUNT-4 (36 weeks open-label + 52 weeks) (169) | Same as SURMOUNT-1; after 36 weeks, patients on tirzepatide 10 mg or 15 mg were randomized to placebo or tirzepatide | 97.3% | 92.1% | 84.1% | 69.5% |
* Tirzepatide 15 mg/week.
** Tirzepatide 10 mg/15 mg.